Mechanism of action
GLP-1 is released by cells in the small intestine when food arrives. It tells the pancreas to release more insulin when blood sugar is high, lowers the hormone glucagon, slows how fast the stomach empties and acts on appetite centers in the brain. Natural GLP-1 breaks down within minutes. A GLP-1 receptor agonist is built to last much longer, so one dose can work for a day or a full week.
Because the insulin effect depends on blood sugar, GLP-1 receptor agonists used alone carry a low risk of low blood sugar. The effects on the stomach and brain explain both the weight loss and the most common side effects, such as nausea.
History
The first GLP-1 receptor agonist was exenatide, a copy of a peptide found in Gila monster venom. It was approved in the United States as Byetta on April 28, 2005 (see Exenatide and the Gila monster). Liraglutide followed in 2010 and semaglutide in 2017.
Human GLP-1 itself was described in the 1980s. In 1986 and 1987, Svetlana Mojsov and Joel Habener showed that a form of GLP-1 is made in the intestine and raises insulin release. At Novo Nordisk, Lotte Bjerre Knudsen led work that attached a fatty acid to GLP-1 so it binds to albumin and resists breakdown, the design behind liraglutide and semaglutide. The three received the 2024 Lasker-DeBakey Clinical Medical Research Award for this work.
Newer medicines act on more than one hormone receptor. Tirzepatide activates both the GLP-1 and GIP receptors. It is often grouped with GLP-1 medicines, although its label calls it a dual GIP and GLP-1 receptor agonist.
Medical uses
GLP-1 receptor agonists are approved to lower blood sugar in type 2 diabetes. Some products have separate approvals for chronic weight management in adults with obesity, or with overweight plus a weight-related condition. Individual labels also cover lowering the risk of heart attack and stroke, kidney disease in type 2 diabetes, obstructive sleep apnea and a liver disease called MASH.
The same molecule can be sold under different brand names for different uses. Semaglutide is sold as Ozempic for diabetes and as Wegovy for weight management, for example.
Forms and safety
Most GLP-1 receptor agonists are injected under the skin, daily or weekly. Two weight-management tablets are now approved: an oral form of semaglutide and orforglipron, a small-molecule pill. The labels raise the dose step by step to reduce stomach side effects (see titration).
Common side effects of GLP-1 receptor agonists include nausea, diarrhea, vomiting and constipation. Labels for most of these medicines, including semaglutide, tirzepatide, liraglutide and orforglipron, carry a boxed warning about thyroid C-cell tumors seen in rodents. A side-by-side view of the approved options is on our medication comparison page.
See also
References
- Wegovy prescribing information, DailyMed (revised 2026). dailymed.nlm.nih.gov
- Bydureon approval package, NDA 022200, FDA. accessdata.fda.gov
- The discovery and development of GLP-1 based drugs (PNAS 2024, Lasker award essay). ncbi.nlm.nih.gov
- Zepbound prescribing information, DailyMed (revised 2026). dailymed.nlm.nih.gov
- FDA approves treatment for serious liver disease known as MASH (FDA, August 15, 2025). fda.gov
- Foundayo prescribing information, DailyMed (2026). dailymed.nlm.nih.gov
Last updated . Category: Concepts. Browse all 38 WikiTelehealth entries.